Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. This growth was primarily fueled by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%. TONMYA currently has coverage for approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on January 1, 2027.
The strong commercial performance underscores the market's reception of TONMYA, which is the first new fibromyalgia treatment in over 15 years. The company's CNS commercial infrastructure, which also supports its acute migraine products Zembrace SymTouch and Tosymra, has been pivotal in driving TONMYA's launch. The robust prescription growth and expanding coverage indicate that TONMYA is gaining traction among physicians and patients, positioning Tonix for sustained revenue growth in the coming quarters.
Beyond its commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, a significant step toward addressing a large unmet medical need. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These pipeline advancements highlight Tonix's commitment to developing innovative therapies in CNS and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides the company with the flexibility to execute its commercial and clinical strategies without immediate funding constraints.
The positive quarterly results and pipeline progress are likely to bolster investor confidence in Tonix's growth trajectory. As TONMYA continues to penetrate the fibromyalgia market and the company advances its late-stage programs, Tonix is positioning itself as a key player in CNS therapeutics. The company's focus on high unmet medical needs and its integrated commercial infrastructure provide a solid foundation for future value creation.
